Are there any prostate cancer biomarker tests that help inform my treatment plan?
Whether you are newly diagnosed with prostate cancer or have advanced prostate cancer, prostate cancer biomarker tests (PCM) provide additional information that can help guide treatment.
When it comes to treating (and beating) prostate cancer, more information can be better. Will radiation be effective? Will I benefit from chemotherapy? Prostate cancer biomarker tests (PCMs) look for molecules in the blood, urine or tissue that can provide additional insights about your prostate cancer treatment and help inform what you choose to do next, even if you have advanced prostate cancer.
If you are in the treatment phase of fighting prostate cancer, PCMs can provide more insights if you:
- have already had a prostatectomy
- are deciding to move forward with radiation
- have had radiation and have undergone another biopsy and need more information about possible next steps
For patients with advanced prostate cancer, time is of the essence. You and your healthcare provider will want to choose the best, most effective treatment plan. One PCM test — AR-V7 — can determine whether or not you may respond to androgen receptor (AR) targeted therapies. Rather than waste time trying a therapy that won’t be effective, this blood test gives you and your healthcare provider clear answers so you can feel confident in your treatment plan.
PCM Test After a Radical Prostatectomy
If you’ve had a radical prostatectomy, deciding what to do next can be overwhelming. This PCM can provide more insights about whether or not additional treatment may be beneficial.
Decipher Radical Prostatectomy (RP) is a tissue based prostate cancer marker (PCM) than can be effective in helping a high-risk patient and their healthcare provider determine if additional treatment following radical prostatectomy could be effective.
PCM Tests If You're Considering Radiation
If you are considering radiation, you might consider the following tests to help inform your treatment plan. Or, if you have had radiation and underwent another biopsy, the following PCM tests could help you and your healthcare provider assess whether you may need additional treatment down the line. Please keep in mind that many radiation oncologists may want to wait until your PSA rises +2ng/mL above the lowest point after your radiation to see if further biopsies or treatment are necessary.
Also known as Decipher Biopsy, this genomic test analyzes individual tumor aggressiveness and combines it with an individual’s clinically validated prostate cancer-specific mortality risk and personal risk of metastasis.
The Prolaris Score for prostate cancer analyzes the biology of the prostate cancer tumor as well as how fast the cells in the tumor are dividing (cancer aggressiveness).
Genomic Prostate Score
GPS is a powerful test for men with organ confined prostate cancer looking for more insights about whether or not to pursue treatment or an active surveillance protocol.
PCM Test for Late-Stage Prostate Cancer
This PCM test is for patients with late-stage prostate cancer and tells whether androgen receptor (AR) targeted therapies could be an effective treatment approach.
For men with mCRPC (metastatic castration-resistant prostate cancer), this blood test shows if androgen receptor (AR) targeted therapies could be an effective treatment approach.
Prostate Cancer Treatment FAQs
Prostate cancer biomarkers (PCMs) are molecules found in blood, tissue, or body fluids. PCMs are revolutionary new, non-invasive diagnostic tests that may help your healthcare provider decide if your prostate cancer is in fact low risk, if something more aggressive may be lurking in your prostate, or if there are hot spots in the prostate that may need to be re-evaluated upon biopsy. PCMs also can help you and your healthcare provider determine the most appropriate treatment for your cancer.
If you have had a prostatectomy and are at risk of your cancer spreading or recurring, the following PCMs could be helpful:
If your physician has recommended radiation to treat your prostate cancer, the following tests can help inform your treatment plan. Or, if you have had radiation and underwent another biopsy, these tissue-based tests could help you and your healthcare provider assess whether you may need additional treatment down the line. However, many radiation oncologists may want to wait until your PSA rises +2ng/ml above the lowest point after your radiation to see if further biopsies or treatment are necessary.
A medicine that targets a specific receptor present in some prostate cancers is used to treat qualifying patients with late-stage cancer. This PCM test can help determine if you are a candidate for androgen receptor (AR) targeted therapies.